View More Recent Stories

Sep 8, 2025 08:30AM ImmunityBio reports ANKTIVA therapy reverses lymphopenia in lung cancer
Aug 26, 2025 08:31AM ImmunityBio reports early trial results in brain cancer treatment
Aug 13, 2025 08:31AM ImmunityBio reports complete responses in lymphoma trial with CAR-NK therapy
Aug 5, 2025 07:31AM ImmunityBio, Inc. (IBRX) Tops Q2 EPS by 1c
Jul 25, 2025 06:06AM ImmunityBio raises $80 million from institutional investors
Jun 4, 2025 06:46AM H.C. Wainwright Reiterates Buy Rating on Immunitybio Inc (IBRX)
Jun 2, 2025 09:02AM ImmunityBio (IBRX) receives FDA Expanded Access for Cancer BioShield platform
May 20, 2025 06:43AM Piper Sandler Upgrades Immunitybio Inc (IBRX) to Overweight, 'ANKTIVA Growing w/ Expansion Opps'
May 13, 2025 04:32PM BTIG Reiterates Buy Rating on Immunitybio Inc (IBRX)
May 12, 2025 06:36AM ImmunityBio, Inc. (IBRX) Misses Q1 EPS by 2c
May 5, 2025 07:51AM ImmunityBio (IBRX) receives Refusal to File letter from FDA for sBLA for use of ANKTIVA plus Bacillus Calmette-Guerin
Apr 29, 2025 07:25AM H.C. Wainwright Reiterates Buy Rating on Immunitybio Inc (IBRX)
Apr 15, 2025 08:01AM ImmunityBio (IBRX) Announces FDA Submissions of Supplemental BLA for NMIBC Papillary Disease and for Expanded Access of ANKTIVA® to Treat Lymphopenia
Apr 8, 2025 07:32AM ImmunityBio (IBRX) Announces Execution of $75 Million Equity Financing with an Institutional Investor
Mar 14, 2025 06:49AM H.C. Wainwright Reiterates Buy Rating on Immunitybio Inc (IBRX)
Mar 6, 2025 06:03AM H.C. Wainwright Starts Immunitybio Inc (IBRX) at Buy
Mar 3, 2025 04:23PM ImmunityBio, Inc. (IBRX) Tops Q4 EPS by 8c
Feb 28, 2025 09:11AM ImmunityBio (IBRX) Receives FDA RMAT Designation for ANKTIVA and CAR-NK
Feb 19, 2025 09:01AM ImmunityBio (IBRX): FDA Authorizes ImmunityBio to Provide Recombinant BCG (rBCG) to Urologists to Address TICE® BCG Shortage
Feb 13, 2025 03:06PM ImmunityBio (IBRX) Announces UK MHRA Accepted MAA for ANKTIVA for Treatment of Patients with BCG-unresponsive Non-Muscle Invasive Bladder Cancer Carcinoma
Jan 29, 2025 08:39AM ImmunityBio (IBRX) Announces Collaboration with BeiGene on Confirmatory Phase 3 Trial of ANKTIVA® and PD-1 Checkpoint Inhibitor Combination in Non-Small Cell Lung Cancer
Jan 16, 2025 03:03PM ImmunityBio (IBRX) Provides Regulatory Update on Anticipated FDA Submissions in 2025 Following Meeting with the Agency (earlier)
Jan 10, 2025 06:06AM BTIG Starts Immunitybio Inc (IBRX) at Buy
Jan 6, 2025 09:03AM ImmunityBio (IBRX) Announces Permanent J-code (J9028) for ANKTIVA® Is Now Effective
Dec 11, 2024 07:31AM ImmunityBio (IBRX) Prices 33.33M Sharee Offering at $3/sh
Dec 10, 2024 04:24PM ImmunityBio (IBRX) Announces Proposed Public Offering of Common Stock
Nov 21, 2024 10:01AM ImmunityBio (IBRX) and nCartes Enter Collaboration Agreement on Clinical Trial Data Fulfillment
Nov 12, 2024 04:33PM ImmunityBio, Inc. (IBRX) Tops Q3 EPS by 4c
Oct 25, 2024 03:19PM ImmunityBio (IBRX) call put ratio 9.6 calls to 1 put with a focus on November 4.5, November 7 and January 10 calls
Oct 23, 2024 07:12AM EF Hutton Starts Immunitybio Inc (IBRX) at Buy
Sep 9, 2024 08:32AM ImmunityBio (IBRX) Presents Positive Long-Term Overall Survival Data in Non-Small Cell Lung Cancer Patients and Announces Registrational Intent Phase 3 Trials with ANKTIVA and Checkpoint Immunotherapy
View More Recent Stories